Cite
APA Citation
Munster, P., Krop, I., LoRusso, P., Ma, C., Siegel, B., Shields, A., Molnár, I., Wickham, T., Reynolds, J., Campbell, K., Hendriks, B., Adiwijaya, B., Geretti, E., Moyo, V., & Miller, K. (2018). safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British journal of cancer, 119(9), 1086–1093. http://access.bl.uk/ark:/81055/vdc_100086829791.0x0001cb